<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384888</url>
  </required_header>
  <id_info>
    <org_study_id>Eliane Araújo de Oliveira</org_study_id>
    <nct_id>NCT03384888</nct_id>
  </id_info>
  <brief_title>Neurostimulation Applied to Fibromyalgia</brief_title>
  <acronym>NeuroFibro</acronym>
  <official_title>Neurostimulation Applied to Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Paraíba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Paraíba</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NeuroFibro is a double-blind, randomized, placebo-controlled clinical trial, using
      neurostimulation in women with fibromyalgia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The parallel clinical trial simultaneously compares two groups of individuals, one of which receives the intervention of interest and the other is a control group (sham).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in pain level, assessed by Visual Analogue Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in quality of life level assessed by Fibromyalgia Impact Questionnaire (FIQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health assessment</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in health assessed level assessed by Fibromyalgia Health Assessment Questionaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in sleep quality assessed by Pittsburgh Sleep Quality Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in the cognitive function assessed by Mini Mental State Examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in the anxiety level assessed by Beck Anxiety Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in the depression level assessed by Beck Depression Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical electrical activity</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in the cortical electrical activity assessed by electroencephalogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resilience</measure>
    <time_frame>Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)</time_frame>
    <description>Changes in the resilience assessed by Wagnild and Young Resilience Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>ano-M1-cat-SO5 tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ano-M1-cat-SO10 tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.</description>
    <arm_group_label>ano-M1-cat-SO5 tDCS</arm_group_label>
    <arm_group_label>ano-M1-cat-SO10 tDCS</arm_group_label>
    <other_name>Transcranial direct current stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.</description>
    <arm_group_label>Sham tDCS</arm_group_label>
    <other_name>Transcranial direct current stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) diagnosis of fibromyalgia, according to the American College of Rheumatology
             criteria; (2) been diagnosed for at least three months; (3) be female; (4) be in the
             age group between 25 and 60 years of age; and (5) sign the consent form.

        Exclusion Criteria:

          -  (1) cognitive deficit, evaluated through the Mini Mental State Examination (MMSE); (2)
             illiterate; (3) people with metallic implants located on the head, cochlear implants
             and cardiac pacemaker; (4) history of convulsion; (5) severe depression, measured by
             score greater than 36 on Beck Depression Inventory; and (6) be pregnant.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eliane Oliveira, Dr</last_name>
    <phone>55 (83) 3216-7200</phone>
    <email>elianeao@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Géssika Melo</last_name>
    <phone>55 (83) 3216-7200</phone>
    <email>gessika.fisio@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal da Paraiba</name>
      <address>
        <city>João Pessoa</city>
        <state>Paraíba</state>
        <zip>58.051-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eliane Oliveira, Dr</last_name>
      <phone>55 (83) 3216-7200</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Paraíba</investigator_affiliation>
    <investigator_full_name>Géssika Araújo de Melo</investigator_full_name>
    <investigator_title>Eliane Araújo de Oliveira</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia, Neurostimulation, TDCS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

